Medicare Prescription Drug Modernization Act

Paper Summary:

This paper takes a look at the success of the Medicare Prescription Drug Modernization Act. According to this paper, the US Government claims that it is a vital source for the elderly and disabled Americans. The paper further discusses how many critics have become doubtful about who actually gains from this act. This paper evaluates dynamics of the relationship between the Pharmaceutical lobby and Congress by revealing how this lobby manages to persuade the decision making in Washington.

Outline:
Abstract
Introduction
Statement of the Problem
Literature Review
Research Design
Limitations of the Research
Validity and Reliability of the Results
Conclusion

From the Paper:

"The analytical strategy that will be employed in this paper will firstly identify the gravity of the situation at hand relating to how the drug companies have been influencing the policymaking taking place in Washington and the impact of these policies on the American people as well as, drug companies. Appropriate theories and facts will be given to prove not only the seriousness of the situation but also the validity of the arguments. Also, a brief overview will be given of the past and present situation by evaluating the strengths, weaknesses of the past and present trends and the emerging opportunities and threats. Furthermore, the most pertinent and possible factors relating to the topic (how the drug companies have been influencing the policymaking taking place in Washington and the impact of these policies on the American people as well as, drug companies) will be analyzed and thereafter a thorough examination of possible variables and alternates will be conducted. "

Sample of Sources Used:

• Angell, M. (2004). The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.
• Guyer, J and Schneider, A. (2004). Implications of the New Medicare Law for Dual Eligibles: 10 Key Questions and Answers. Kaiser Family Foundation.
• Gross, D. Schondelmeyer, S.W. and Raetzman, S. (2005). Trends in Manufacturer List Prices of Generic Prescription Drugs Used by Older Americans. AARP Public Policy Institute.
• Ismail, A.M. (2005). Drug Lobby Second to None: How the Pharmaceutical Industry Gets Its Way in Washington. Center for Public Integrity.
• Kanavos, P. Gross, D. and Taylor, D. (2005). Parallel Trading in Medicines: Europe's Experience and Its Implications for Commercial Drug Importation in the United States. AARP Public Policy Institute

More papers on Medicare Prescription Drug Modernization Act:

• Research Paper # 75180 : "Medicare Prescription Drugs"
• Analytical Essay # 116617 : "Medicare Modernization Act"
• Persuasive Essay # 106921 : "Medicare Fair Prescription Drug Act"

APA Citation:

MLA Citation: